Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024


Halle (Saale) / Munich, Germany, December 04, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage biopharmaceutical company developing small molecule drugs to control the function and stability of disease-related proteins, will release its third-quarter 2024 financial results and a business update on Tuesday, December 10, 2024. A public conference call and webcast will accompany the announcement.

Conference call details
Date: December 10, 2024
Time: 3:00 pm CET / 9:00 am ET

The presentation will be accessible via phone and webcast.
The live audio webcast will be available on Vivoryon´s website at:

To participate in the conference call by phone, pre-registration is recommended. Pre-registered participants will receive dial-in instructions for quick access via this website: 

Participants are advised to connect 15 minutes before the start time to ensure timely access.

###


About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based therapies. The company is dedicated to improving the lives of patients with serious illnesses through groundbreaking science. Vivoryon uses its expertise in post-translational modifications to create drugs that regulate the activity and stability of proteins involved in various diseases. The company’s pipeline includes orally administered small molecule inhibitors for Alzheimer’s disease, inflammatory and fibrotic kidney disorders, and cancer.


Vivoryon Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding Vivoryon Therapeutics N.V.’s (the “Company”) business strategy, management plans and objectives for future operations, market estimates and projections for the Company’s products, and forecasts regarding product availability. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should,” and “will,” and similar expressions relating to the Company, are intended to identify forward-looking statements. These statements are not guarantees of future performance but rather reflect management’s current expectations and assumptions about future events and trends, the economy, and other future conditions. These forward-looking statements involve known and unknown risks and uncertainties. These risks and uncertainties, and other factors, could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies, or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. Therefore, undue reliance should not be placed on such forward-looking statements. This press release does not include a full discussion of risk factors. Certain risk factors affecting the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not undertake any obligation to update any information or forward-looking statements contained herein, except as required by law.


For more information, please contact:

Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email:

Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: 

Attachment